Ratchadawan Aeemjinda

Ratchadawan Aeemjinda

Auto-generated profile, based on publicly available information

Ratchadawan Aeemjinda


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RYRitthideach Yorsaeng
Ritthideach Yorsaeng
KAKamolthip Atsawawaranunt
Kamolthip Atsawawaranunt
NSNungruthai Suntronwong
Nungruthai Suntronwong
SKSitthichai Kanokudom
Sitthichai Kanokudom
JCJira Chansaenroj
Jira Chansaenroj
YPYong Poovorawan
Yong Poovorawan
The Coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), continues to surge despite the widespread use of vaccination. In Thailand, more than 77% and 39% of the population received two doses and three doses of COVID-19 vaccines as of December 2022, respectively. In addition, during the Omicron predominant period in 2022, more than 70% of Thai individuals have been infected. To gain comprehensive insight into SARS-CoV-2 antibody dynamics following vaccination or following vaccination and infection (hybrid immunity), we performed a cross-sectional analysis of sera samples from individuals who received COVID-19 vaccination and/or have been infected with COVID-19 in Thailand between January 2021 and December 2022. A total of 4126 samples were collected. Humoral immunity was evaluated by quantifying the immunoglobulin (including IgG, IgM, and IgA isotypes) specific to the SARS-CoV-2 receptor-binding domain (RBD) or Ig anti-RBD. The results showed that individuals who received two-dose vaccination alone had lower levels of Ig anti-RBD, which rapidly waned over time. To restore the waning antibody, a third dose vaccination is recommended for uninfected individuals who have only received 2 doses.

1 March 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SKSitthichai Kanokudom
Sitthichai Kanokudom
JCJira Chansaenroj
Jira Chansaenroj
NSNungruthai Suntronwong
Nungruthai Suntronwong
Suvichada AssawakosriSuvichada Assawakosri
Suvichada Assawakosri
RYRitthideach Yorsaeng
Ritthideach Yorsaeng
YPYong Poovorawan
Yong Poovorawan
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines. This prospective cohort study was conducted between June and October 2022. The self-recorded reactogenicity was evaluated on the subsequent 7 days after a fourth dose. The binding and neutralizing activity of antibodies against the Omicron BA.4/5 variants were determined. Overall, 292 healthy adults were enrolled and received BNT162b2 or mRNA-1273. Reactogenicity was mild to moderate and well tolerated after a few days. Sixty-five individuals were excluded. Thus, 227 eligible individuals received a fourth booster dose of BNT162b2 (n = 109) and mRNA-1273 (n = 118). Most participants, regardless of the type of previous three-dose regimens, elicited a significantly high level of binding antibodies and neutralizing activity against Omicron BA.4/5 28 days after a fourth dose. The neutralizing activity against Omicron BA.4/5 between the BNT162b2 (82.8%) and mRNA-1273 (84.2%) groups was comparable with a median ratio of 1.02. This study found that the BNT162b2 and mRNA-1273 vaccines can be used as a fourth booster dose for individuals who were previously immunized with any prior three-dose mix-and-match COVID-19 vaccine regimens.

Verified
Journal Article
Open access
PDF file
NSNungruthai Suntronwong
Nungruthai Suntronwong
PVPreeyaporn Vichaiwattana
Preeyaporn Vichaiwattana
JPJiratchaya Puenpa
Jiratchaya Puenpa
SPSiripat Pasittungkul
Siripat Pasittungkul
RARatchadawan Aeemjinda
Ratchadawan Aeemjinda
YPYong Poovorawan
Yong Poovorawan
Since the emergence of COVID-19, the epidemiological and seasonal patterns of respiratory pathogens have shifted, highlighting the need for ongoing surveillance. This study investigated the epidemiology, seasonal trends, and age-specific detection of respiratory viruses among patients with acute respiratory infections (ARIs) in Thailand from January to December 2024. Eight respiratory viruses were detected using multiplex real-time RT-PCR. Of 7853 samples, 60.8% (4777) tested positive. The most frequently detected pathogens were influenza virus (IFV, 24.8%), SARS-CoV-2 (21.5%), and human rhinovirus (HRV, 20.8%). IFV showed biannual peaks during the cold and rainy seasons, SARS-CoV-2 peaked in the warm months, and HRV circulated year-round. Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) were primarily detected during the rainy season (July–November), reflecting a return toward pre–COVID-19 seasonal patterns. Age-specific differences were notable: HRV was most prevalent in children < 5 years, IFV predominated among those aged 6–18 years, and adults ≥ 19 years were mainly positive for IFV and SARS-CoV-2. Co-infections were most frequent in children aged 3–5 years, often involving HRV. These findings provide updated insights into post–COVID-19 viral epidemiology, emphasize the importance of age- and season-specific surveillance, and support the development of effective public health strategies for ARI control.

19 January 2023 in medRxiv
Verified
Preprint
Open access
PDF file
SKSitthichai Kanokudom
Sitthichai Kanokudom
JCJira Chansaenroj
Jira Chansaenroj
NSNungruthai Suntronwong
Nungruthai Suntronwong
Suvichada AssawakosriSuvichada Assawakosri
Suvichada Assawakosri
RYRitthideach Yorsaeng
Ritthideach Yorsaeng
YPYong Poovorawan
Yong Poovorawan
Objective To investigate the reactogenicity and immunogenicity of the fourth dose using mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines. Methods This prospective cohort study was conducted between June and October 2022. The self-recorded reactogenicity was evaluated on the subsequent 7 days after a fourth dose. Binding and neutralizing activity of antibodies against the Omicron BA.4/5 variants were determined. Results Overall, 292 healthy adults were enrolled and received BNT162b2 or mRNA-1273. Reactogenicity was mild to moderate and well-tolerated after a few days. Sixty-five individuals were excluded. Thus, 227 eligible individuals received a fourth booster dose of BNT162b2 (n=109) and mRNA-1273 (n=118). Most participants, regardless the type of previous three dose regimens, elicited a significantly high level of binding antibodies and neutralizing activity against the Omicron BA.4/5 28 days after a fourth dose. The neutralizing activity against the Omicron BA.4/5 between the BNT162b2 (82.8%) and mRNA-1273 (84.2%) groups was comparable with a median ratio of 1.02. Conclusion This study found that the BNT162b2 and mRNA-1273 vaccines can be used as a fourth booster dose for individuals who were previously immunized with any prior mix and match three dose COVID-19 vaccine.

4 June 2025 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
PIPhattharaporn Inma
Phattharaporn Inma
PNPornjarim Nilyanimit
Pornjarim Nilyanimit
NWNasamon Wanlapakorn
Nasamon Wanlapakorn
RARatchadawan Aeemjinda
Ratchadawan Aeemjinda
SKSumeth Korkong
Sumeth Korkong
YPYong Poovorawan
Yong Poovorawan
: Hepatitis A virus (HAV) is an RNA virus that causes acute hepatitis and is transmitted via the fecal–oral route. It has historically been highly endemic in Thailand, where most children develop lifelong immunity after infection. Economic development and improved sanitation have reduced HAV transmission, but immunity levels have declined, raising concerns about potential future outbreaks. This study aims to assess the seroprevalence of HAV antibodies in Thailand in 2024, 10 years after the last national survey in 2014, and to evaluate current immunity levels to inform public health strategies. A cross-sectional study was conducted in a population aged 6 months to 80 years across Thailand’s geographic regions. A total of 4,312 serum samples were tested for anti-HAV antibodies using the chemiluminescent microparticle immunoassay. The seroprevalence data were compared with findings from previous surveys in 2004 and 2014. The study showed a significant decline in population immunity to HAV, with the age at which 50% of individuals had antibodies increasing from 36 in 2004 to 42 in 2014, and to 47 years in 2024. A majority of the population remained susceptible to HAV, particularly among younger age groups. Thailand has transitioned to low HAV endemicity, with a large proportion of the population lacking immunity. Despite the absence of significant outbreaks in recent decades, the risk of future outbreaks remains, particularly from imported cases. Enhanced surveillance and vaccination strategies are necessary to prevent future HAV transmission and manage public health risks.

7 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SKSitthichai Kanokudom
Sitthichai Kanokudom
JCJira Chansaenroj
Jira Chansaenroj
Suvichada AssawakosriSuvichada Assawakosri
Suvichada Assawakosri
NSNungruthai Suntronwong
Nungruthai Suntronwong
RYRitthideach Yorsaeng
Ritthideach Yorsaeng
YPYong Poovorawan
Yong Poovorawan
This study investigated the impact of hybrid immunity on antibody responses in the participants who received two to seven doses of the COVID-19 vaccine. The study was conducted between April and June 2023. Out of 771 serum samples analyzed, 71.7% exhibited hybrid immunity (positive for total anti-N Ig), while 28.3% showed vaccine-induced immunity (negative for total anti-N Ig). Participants were categorized based on the number of vaccine doses: 2, 3, 4, and ≥5. The findings highlight a trend where a higher number of vaccine doses received was associated with a lower infection rate. There was no significant difference in total RBD Ig levels between those who received 3, 4, or ≥5 doses in both the hybrid immunity and vaccination alone groups across all observed durations as follows: <6 months, 6 to <9 months, 9 to <12 months, and ≥12 months. Hybrid immunity consistently maintained higher total RBD Ig levels and durability compared to vaccination alone, with estimated half-lives (T1/2) of 189.5 days versus 106.8 days for vaccine alone. This investigation underscored the potential benefit of hybrid immunity and raised questions about the optimal strategies for further vaccine dosing.